【美诺华:富马酸丙酚替诺福韦原料药通过CDE技术审评】财联社5月27日电,美诺华公告,控股子公司富马酸丙酚替诺福韦原料药通过CDE技术审评。该药品适于治疗成人和青少年慢性乙型肝炎。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”